Ablynx logo

Ablynx

Proprietary therapeutic proteins for treating life-threatening diseases

115 employees · est. 2001 · Belgium

VS
DotBio logo

DotBio

18 employees · est. 2018 · Singapore, Singapore

Ablynx is the older company (2001 vs 2018); Ablynx is the larger of the two.

Side-by-Side Comparison

Ablynx DotBio
Founded
2001 older 2018
Headquarters
Belgium Singapore, Singapore
Employees
115 larger 18
Industry
Not tracked yet Biotechnology, Life Sciences
Funding Stage
Acquired Seed
Total Funding
$4.37B $8.15M
Funding Rounds
11 4
Services
Not tracked yet Not tracked yet
Target Customers
Not tracked yet Not tracked yet
Taxonomy
Nanobodies, Therapeutic Proteins, Single-Domain Antibody Fragments, Inflammation Treatment, Hematology, Immuno-oncology, Oncology, Biotechnology Innovation, Multi-specific Molecules, Drug Development, Proprietary Technologies, Life-threatening Diseases, Acquisition Strategy, Biopharmaceuticals, Targeted Therapies Immuno-oncology Drugs, Domain Antibodies, DotBody Technology, Multi-specific Antibodies, Humanized Antibodies, Stable Antibodies, Protein Engineering, Antibody Engineering, Biopharmaceuticals, Cancer Treatment, Therapy Development, Drug Development, Therapeutic Antibodies, Medical Research
Website
ablynx.com dotbiopharma.com
Ablynx logo

About Ablynx

Ablynx, a Sanofi company headquartered in Belgium, is innovating in the biotechnology sector with its development of Nanobodies®. These proprietary therapeutic proteins merge the benefits of conventional antibodies with characteristics of small-molecule drugs to combat life-threatening diseases. Th...

DotBio logo

About DotBio

DotBio is a Singapore-based biotechnology startup founded in 2018. The company focuses on developing innovative immuno-oncology drugs utilizing their proprietary DotBodies technology. This technology, conceived by Professor Pär Nordlund and Dr. Ignacio Asial at Singapore’s Nanyang Technological Univ...

We will tell you when either one moves

BounceWatch watches Ablynx and DotBio for new funding, fast hiring, new executives and a change of software vendor. When one happens, we email you the same day.

Watch both — free

Funding, hiring, leadership and stack changes at Ablynx and DotBio — by email.

Frequently Asked Questions

Ablynx — Proprietary therapeutic proteins for treating life-threatening diseases. DotBio. Both companies operate in related markets but may differ in funding stage, team size, and product focus.
Ablynx has raised $4.37B while DotBio has raised $8.15M.
Ablynx and DotBio operate in overlapping markets and are frequently compared. Track both companies on Bounce Watch to monitor their growth signals in real time.

Compare Ablynx with someone else

Start typing a company name or domain.

Compiled from the BounceWatch company index. We last looked at Ablynx on 11 Jun 2026, and DotBio on 12 Sep 2024. Where a field is blank here, it means we have not recorded it — not that the answer is zero. How we source and date this.

One analytics cookie (Google Analytics). Cookie Policy